454 Life Sciences Corp., of Branford, Conn., appointed Katherine Webster vice president for measurement services center sales.
Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Robert Zerbe to its board.
Abingworth Management, of London, appointed Andy Sandham venture partner.
Acadia Pharmaceuticals Inc., of San Diego, appointed David Furlano vice president, regulatory affairs.
AEterna Zentaris Inc., of Quebec City, appointed Gerald Martin to its board.
Affymax Inc., of Palo Alto, Calif., appointed Paul Cleveland chief financial officer and executive vice president of corporate development, and Christopher Damman vice president of business development.
Alfacell Corp., of Bloomfield, N.J., formed a thoracic cancer advisory board, which includes Michele Carbone as chairman, and members Harvey Pass and Raja Flores. It also appointed Tommy Thompson special adviser.
Alimera Sciences Inc., of Atlanta, appointed Richard Eiswirth chief financial officer.
Ambit Biosciences, of San Diego, appointed Donald Myll senior vice president commercial operations and chief financial officer.
American Pharmaceutical Partners Inc., of Schaumburg, Ill., and American BioScience Inc., of Santa Monica, Calif., appointed Carlo Montagner president of Abraxis Oncology.
Amicus Therapeutics, of Cranbury, N.J., appointed David Lockhart chief scientific officer.
Anadys Pharmaceuticals Inc., of San Diego, appointed Francis Chisari to its clinical and scientific advisory board.
Anika Therapeutics Inc., of Woburn, Mass., appointed Raymond Land new independent director of its board.
Arginox Pharmaceuticals, of Redwood City, Calif., appointed Robert Terifay president and chief operating officer.
Avigen Inc., of Alameda, Calif., appointed Andrew Sauter vice president of finance.
Axcan Pharma Inc., of Mont-Saint-Hilaire, Quebec, appointed Steve Gannon senior vice president and chief financial officer.
BioAlliance Pharma, of Paris, appointed Florence Dupre vice president of sales and marketing.
BioDelivery Sciences International Inc., of Morrisville, N.C., appointed Mark Salyer executive vice president of sales and marketing.
Cardium Therapeutics Inc., of San Diego, appointed Randall Moreadith executive vice president and chief medical officer.
Celsion Corp., of Columbia, Md., appointed William Hahne vice president clinical development and medical affairs, and Christopher Black executive director, preclinical research.
Chronogen Inc., of Montreal, appointed Jean-Marie Houle vice president of research and development.
CMEA Ventures, of San Francisco, appointed Andrea Tobias partner.
Codexis Inc., of Redwood City, Calif., appointed Robert Breuil senior vice president and chief financial officer.
Corgentech Inc., of South San Francisco, promoted Rolf Ehrhardt to vice president, preclinical development; Melissa Morandi to vice president, quality assurance; Patricia Richards to vice president, clinical research; and Jennifer Cook Williams to vice president, investor relations.
CV Therapeutics Inc., of Palo Alto, Calif., appointed Joseph Davie to its board.